ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin) and endothelial dysfunction in sepsis: Marker or culprit?

Critical Care Medicine

Volumn 35, Issue 10, 2007, Pages 2453-2454

  Levy, Bruno ^a,b   Lacolley, Patrick ^a,b   Regnault, Veronique ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

ADAMTS 13; Endothelial dysfunction; Organ failure; Sepsis; Von Willebrand factor

Indexed keywords

BIOLOGICAL MARKER; DROTRECOGIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

DISSEMINATED INTRAVASCULAR CLOTTING; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME DEFICIENCY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTENSIVE CARE; PLASMA TRANSFUSION; PRIORITY JOURNAL; SEPSIS;

ADAM PROTEINS; ENDOTHELIUM; HUMANS; SEPSIS; VON WILLEBRAND FACTOR;

EID: 34748891799     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000284735.46290.05     Document Type: Editorial

References (14)

1. Abraham E, Laterre PF, Garg R, et al: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
2. Kalil AC, Coyle SM, Um JY, et al: Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004; 21:222-229
3. Blann AD: Plasma von Willebrand factor, thrombosis, and the endothelium: The first 30 years. Thromb Haemost 2006; 95:49-55
4. Chauhan AK, Motto DG, Lamb CB, et al: Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006; 203:767-776
5. Martin K, Borgel D, Lerolle N, et al: Decreased a disintegrin-like and metalloprotease with thrombospondin (ADAMTS)-13 is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007; 35:2375-2382
6. Bianchi V, Robles R, Alberio L, et al: Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: A severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100:710 -713
7. Loof AH, van Vliet HH, Kappers-Klunne MC: Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura. Br J Haematol 2001; 112:1087-1088
8. Mannucci PM, Canciani MT, Forza I, et al: Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98:2730-2735
9. Mannucci PM, Vanoli M, Forza I, et al: Von Willebrand factor cleaving protease (ADAMTS13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 2003; 88:914-918
10. Moore JC, Hayward CP, Warkentin TE, et al: Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98:1842-1846
11. Ono T, Mimuro J, Madoiwa S, et al: Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood 2006; 107:528-534
12. Nguyen TC, Liu A, Liu L, et al: Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007; 92:121-124
13. Nguyen TC, Carcillo JA: Bench-to-bedside review: Thrombocytopenia- associated multiple organ failure - A newly appreciated syndrome in the critically ill. Crit Care 2006; 10:235
14. Plaimauer B, Scheiflinger F: Expression and characterization of recombinant human ADAMTS-13. Semin Hematol 2004; 41:24-33